Kraig Biocraft Laboratories files for International Patents in Key Spider Silk Knock-in Knock-out Technology

Rhea-AI Summary

Kraig Biocraft Laboratories (OTCQB: KBLB) has filed a patent for its advanced spider silk mass production technologies, particularly focusing on knock-in knock-out gene editing systems for nearly pure spider silk fibers. This application, titled "Modification of Heavy Chain Fibrion in Bombyx Mori," builds on a provisional patent filed in February 2020. CEO Kim Thompson stated that the filing is timely as the company intends to transition this new technology to production soon, emphasizing its core role in commercialization and sales.

Positive

• Patent filed for advanced spider silk production technologies.
• Protection of intellectual property through international patent application.
• Technological advancements leading to nearly pure spider silk fibers.

Negative

• None.

Patent covers Biotech Company’s latest Spider Silk mass production Tools

ANN ARBOR, Mich., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company has filed a patent application protecting its most advanced knock-in knock-out gene editing technologies for the creation of nearly pure spider silk.

Entitled "Modification of Heavy Chain Fibrion in Bombyx Mori", this patent covering the core technologies the Company has developed for the mass production of nearly pure spider silk fibers. Specifically, the Company has leveraged the application of knock-in knock-out technology to create the most genetically advanced and purest spider silk fibers in the Company’s history. The Company has also filed a corresponding patent application under the global Patent Cooperation Treaty process to protect these technologies internationally.

These technologies and inventions were first disclosed in a provisional patent filed with the United States Patent and Trademark Office (USPTO) under applications #62/995,717 on February 11, 2020. This full patent application, now filed, takes advantage of that earlier priority date in the USPTO’s first to file patent system. The Company made the discovery of this breakthrough public during a press conference held on April 16, 2020 where it reported the creation of this new technology with a spider silk purity nearly ten times greater than Dragon Silk, the Company’s previously developed recombinant spider silk fibers.

"Since first reporting the development of this new Knock-in, Knock-out gene-editing system, we have moved forward rapidly to bring this nearly pure spider silk to market. The filing of this full patent application is well-timed as we expect to begin transitioning this new, purer spider silk technology to our production facility in the near future," said Kim Thompson, CEO and founder of Kraig Labs. “These technologies are core to the commercialization of spider silk, and we will continue to push forward aggressively to protect and grow intellectual property while we remain squarely focused on the commercialization and generating sales.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.:

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include future sales of SpydaSilk™ and descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

FAQ

What is Kraig Biocraft Laboratories' recent patent about?

Kraig Biocraft Laboratories recently filed a patent for advanced technologies in spider silk mass production, specifically focusing on gene editing techniques.

When did Kraig Biocraft Laboratories file its patent application?

The patent application was filed on February 16, 2021.

What are the implications of the new patent for KBLB?

The new patent enhances the company's ability to produce nearly pure spider silk fibers, which is crucial for its commercialization strategy.

How does the new technology compare to previous spider silk products?

The new technology offers spider silk purity nearly ten times greater than the previously developed Dragon Silk.

Is Kraig Biocraft Laboratories pursuing international patent protection?

Yes, the company has filed a corresponding patent application under the global Patent Cooperation Treaty.